Certuity LLC Makes New $204,000 Investment in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Certuity LLC bought a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,053 shares of the biotechnology company’s stock, valued at approximately $204,000.

A number of other hedge funds have also recently modified their holdings of the stock. Creative Planning lifted its holdings in shares of Corcept Therapeutics by 18.2% in the 2nd quarter. Creative Planning now owns 11,626 shares of the biotechnology company’s stock valued at $378,000 after purchasing an additional 1,794 shares during the last quarter. Cetera Investment Advisers increased its position in Corcept Therapeutics by 6.2% during the second quarter. Cetera Investment Advisers now owns 38,292 shares of the biotechnology company’s stock worth $1,244,000 after buying an additional 2,244 shares during the period. CWM LLC lifted its stake in Corcept Therapeutics by 81.5% in the third quarter. CWM LLC now owns 8,976 shares of the biotechnology company’s stock valued at $415,000 after buying an additional 4,030 shares during the last quarter. nVerses Capital LLC lifted its stake in Corcept Therapeutics by 43.6% in the third quarter. nVerses Capital LLC now owns 5,600 shares of the biotechnology company’s stock valued at $259,000 after buying an additional 1,700 shares during the last quarter. Finally, AlphaMark Advisors LLC boosted its holdings in shares of Corcept Therapeutics by 2,269.6% in the third quarter. AlphaMark Advisors LLC now owns 9,739 shares of the biotechnology company’s stock valued at $451,000 after acquiring an additional 9,328 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Canaccord Genuity Group lifted their price objective on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, January 30th. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Corcept Therapeutics in a research note on Friday, February 7th. Finally, StockNews.com cut Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $88.25.

Corcept Therapeutics Stock Performance

NASDAQ:CORT opened at $73.61 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The firm has a market cap of $7.71 billion, a PE ratio of 58.42 and a beta of 0.58. The firm has a 50 day simple moving average of $57.45 and a 200-day simple moving average of $48.88. Corcept Therapeutics Incorporated has a 1-year low of $20.84 and a 1-year high of $73.75.

Insider Buying and Selling at Corcept Therapeutics

In other news, insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $50.39, for a total value of $1,007,800.00. Following the transaction, the insider now directly owns 85,318 shares of the company’s stock, valued at $4,299,174.02. The trade was a 18.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $50.54, for a total transaction of $111,188.00. The disclosure for this sale can be found here. Insiders sold 28,011 shares of company stock worth $1,479,608 in the last 90 days. 20.50% of the stock is owned by company insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.